CBIO

Crescent Biopharma, Inc.

Healthcare
Biotechnology
$721M market cap

Forecast run · Sep 14, 2026Upside rank 435 of 3,136

Model Signal

ForecastQ Daily Probabilities

57.3%

62.9%

41.1%

Analyst Consensus

Recommendation2.36/5 Buy

Last price$19.41

Price target$31.25

Implied move+61.0%

Analysts14

ForecastQ Portfolios

CBIO is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.